Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Fig. 1

Second- and third-line treatment in patients with EGFR Mut + NSCLC More than one agent could be reported. *Other = experimental (n = 4 s-line), afatinib (n = 3 s-line), experimental afatinib (n = 2 third-line), gefitinib/placebo (n = 1 s-line), trofosfamide (n = 1 s-line). Data for patients receiving second-line treatment are a combination of planned treatment (n = 63 patients who did not consent to collection of data for second-line treatment) and actual treatment (n = 59 patients who consented to collection of data for second and subsequent lines of treatment). Mut+, mutation-positive; NSCLC, non-small-cell lung cancer

Back to article page
\